Siponimod for treating secondary progressive multiple sclerosis – guidance (TA656)

Siponimod is recommended as an option for treating secondary progressive multiple sclerosis with evidence of active disease (that is, relapses or imaging features of inflammatory activity) in adults.

National Institute for Health and Care Excellence